Drug Database
MO

mometasone furoate (Monovo / H527722 / Mundoson)

✓ Approved

Almirall, S.A · NR3C1 · Small Molecule

What is mometasone furoate?

mometasone furoate is a small molecule developed by Almirall, S.A. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesMonovo, H527722, Mundoson
CompanyAlmirall, S.A
Drug ClassSmall Molecule
Molecular TargetNR3C1, NR3C2
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Almirall, S.A

Mechanism of Action

Molecular Targets

mometasone furoate acts on 2 molecular targets:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

mometasone furoate is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

Related Research Articles

PubMedJournal of pharmaceutical sciences2026-08-29

A combined approach for full API particle size distribution characterization in nasal spray suspensions based on their dissolution behavior.

Cheng Yushan Y, Shu Hong H, Zhang Yingjun Y, Qin Lina L et al.

Determining the particle size distribution (PSD) of the active pharmaceutical ingredient (API) in nasal spray suspensions is a challenging task that usually requires the use of morphologically-directed Raman spectroscopy (MDRS). A dissolution-based modeling strategy was established to characterize the entire PSD of starting API in mometasone furoate nasal sprays using dissolution data of finished formulations, whereas MDRS measures API PSD in the final products. A dissolution-PSD model was built in-house to derive the API PSD from the dissolution data of target products, with model parameters estimated using test products with known raw API PSD and dissolution profiles. To obtain representative dissolution data that could better reflect the intrinsic API PSD characteristics of the formulation, different sample pretreatment procedures and dissolution approaches were investigated. The results suggested that the dissolution profile acquired by the paddle method following combined enzymatic hydrolysis and ultrasonication pretreatment was preferable for characterizing the starting API particle size features. Model predictions demonstrated that the commercial Nasonex® displayed a bimodal volume-weighted PSD and a relatively high Dv90 of 15.8 μm, which differed from previous reports. A modified MDRS was applied for cross-checking, and the modeled Dv90 was in agreement with the measured results. Cross-validation for the model using five test batches yielded prediction errors mostly <10%, indicating acceptable performance. For nasal suspension products that typically present complex PSD features, the present method may provide a feasible auxiliary tool for guiding formulation screening and optimizing manufacturing parameters in the preliminary development stage.

PMID 42667955
Read full article →
PubMedBiomedicines2026-08-27

COPD Stability and Asthma Remission: Different Words for the Same Therapeutic Ambition?

Carriera Lorenzo L, Mari Pier-Valerio PV, Lipsi Roberto R, Ielo Simone S et al.

The therapeutic goals related to chronic airway diseases are evolving from short-term symptom control toward sustained suppression of disease activity and prevention of future risk. In severe asthma, this shift has been captured by the concept of clinical remission, generally defined by absence of exacerbations, no need for oral corticosteroids, symptom control, and stable or improved lung function. In chronic obstructive pulmonary disease (COPD), the analogous concept has more often been described as disease stability. Although remission in asthma and stability in COPD have developed within different biological and clinical frameworks, they may reflect disease-specific expressions of the same therapeutic ambition. Recent studies support COPD stability as a measurable and clinically meaningful state, associated with reduced exacerbation risk and mortality. Evidence from optimized inhaled triple therapy, particularly with fluticasone furoate/umeclidinium/vilanterol, indicates that multidimensional stability can be achieved and maintained in a proportion of patients, while real-world studies reinforce its applicability beyond randomized trials. The emergence of biologic therapies for selected patients with eosinophilic or type 2 COPD further strengthens the rationale for considering stability as an ambitious treatment target. In this narrative review, informed by a structured literature search, we discuss the conceptual relationship between asthma remission and COPD stability, and summarize the evidence supporting disease stability as an attainable and prognostically relevant outcome. In addition, we propose a pragmatic multidimensional definition based on symptom stability, absence of moderate or severe exacerbations, no systemic corticosteroid use, and maintained lung function over 12 months. COPD stability should not be viewed as a weaker goal than asthma remission, but rather as the most appropriate COPD-specific expression of sustained low disease activity.

PMID 42652058
Read full article →
PubMedEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026-08-26

Effects of intranasal antihistaminic and corticosteroid therapies on olfactory dysfunction in adults with perennial allergic rhinitis: a prospective comparative study.

Göker Ayşe Enise AE, Aksungur Elif E, Çelik Cem C, Uygan Uğur U et al.

To compare the effects of commonly used intranasal therapies on olfactory dysfunction in adults with perennial allergic rhinitis using objective psychophysical testing. This prospective study included 90 adults with perennial allergic rhinitis and objectively confirmed hyposmia. Patients were allocated into three treatment groups: intranasal azelastine monotherapy, intranasal azelastine plus mometasone furoate combination therapy, and intranasal mometasone furoate monotherapy. Treatments were administered for one month. Olfactory function was assessed before and after treatment using the Sniffin' Sticks test (threshold, discrimination, identification, and composite TDI score). Nasal obstruction was evaluated using the Nasal Obstruction Symptom Evaluation (NOSE) scale. Between-group comparisons of treatment-related change scores and supportive within-group analyses were performed using non-parametric statistical tests. Ninety patients were included, with 30 patients in each treatment group. The mean ages were 29.43 ± 10.58 years in the azelastine group, 29.13 ± 8.79 years in the azelastine plus mometasone furoate group, and 29.90 ± 6.33 years in the mometasone furoate group. Baseline TDI scores were 29.10 ± 1.45, 28.37 ± 2.83, and 27.70 ± 2.34, respectively. Mean ΔTDI was - 3.33 ± 4.14 in the azelastine group, 9.13 ± 4.35 in the combination group, and 11.90 ± 3.82 in the mometasone furoate group, with a significant between-group difference (p < 0.001). In adults with perennial allergic rhinitis and objectively confirmed hyposmia, intranasal corticosteroid-containing regimens were associated with greater improvement in olfactory function than azelastine monotherapy. These findings suggest that intranasal corticosteroid-containing regimens may be preferable when olfactory dysfunction accompanies perennial allergic rhinitis. However, given the non-randomized and open-label design of the study, the results should be interpreted with caution.

PMID 42642529
Read full article →
PubMedClinical case reports2026-08-23

Successful Management and Treatment Rechallenge Following Docetaxel-Induced Serpentine Supravenous Hyperpigmentation With Bullous Features: A Case Report.

Nair Gayathri R GR, Koutsis James J, Poels Deepali D, Agar Nita N et al.

Serpentine supravenous hyperpigmentation (SSH) is a rare dermatological complication of intravenous chemotherapy characterized by linear hyperpigmented streaks along superficial veins. Bullous SSH represents an exceptionally rare variant with only a few previously reported cases in the literature. We report the case of a 50-year-old woman with HER2-positive breast cancer who developed bullous SSH 5 days after her first cycle of TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) chemotherapy. The patient presented with linear erythematous streaks and small tense bullae along the infusion vein on her right forearm. Treatment with topical mometasone furoate 0.1% ointment resulted in complete resolution within 2 weeks. Preventive strategies described for SSH include use of contralateral arm venous access, thorough saline flushing after chemotherapy infusion, consideration of central venous access when feasible, and, in selected cases, modification of the chemotherapy regimen. In our patient, subsequent chemotherapy cycles were administered using contralateral arm venous access with thorough saline flushing (same flushing protocol as Cycle 1), without recurrence of SSH. The patient completed all six planned cycles and subsequently achieved pathologic complete response. This case is the first to demonstrate that conservative management of bullous SSH with topical mometasone furoate, combined with contralateral venous access and thorough saline flushing, enables successful rechallenge and uninterrupted continuation of planned oncological treatment with pathologic complete response as the outcome.

PMID 42632995
Read full article →
PubMedCureus2026-08-21

Total Ophthalmoplegia as an Early Manifestation of Herpes Zoster Ophthalmicus in an Elderly Patient With Asthma: A Case Report.

Gazal Ela E, Karabulut Merve M, Türsen Ümit Ü

Herpes zoster ophthalmicus (HZO) may cause ocular surface disease, but ocular motor cranial neuropathy and total ophthalmoplegia are rare. These neurological deficits generally develop after the cutaneous eruption, making their presence at initial presentation unusual. Asthma has recently gained attention as a risk factor for herpes zoster, potentially through Th2-skewed inflammation, relative Th1-mediated antiviral immune insufficiency, and impaired cellular control of latent varicella-zoster virus (VZV). We report a 71-year-old man with poorly controlled asthma who presented with a one-day history of a right-sided vesicular eruption following four days of severe burning pain in the right scalp and periorbital region. Total ophthalmoplegia was already present at initial evaluation. He had no known diabetes mellitus, hypertension, malignancy, systemic immunosuppression, recent infection, biologic therapy, or chronic systemic corticosteroid use. His only notable comorbidity was asthma, for which fluticasone furoate/umeclidinium/vilanterol had been prescribed, although he used it irregularly. The right eye was fixed, with total ptosis, absent spontaneous movement, and marked restriction in all gaze directions. Presenting uncorrected visual acuity was 0.3 in the right eye and 0.8 in the left eye using decimal notation, and anisocoria was present with absent direct and consensual light reflexes. The diagnosis of HZO was clinical; VZV polymerase chain reaction testing was not performed because of the characteristic painful unilateral vesicular eruption in the ophthalmic dermatome. Contrast-enhanced orbital magnetic resonance imaging was normal, and laboratory evaluation did not reveal any other systemic risk factor, including a negative HIV and viral hepatitis panel. The patient received intravenous acyclovir at 10 mg/kg every eight hours for 21 days, with daily renal function monitoring, as well as a short course of methylprednisolone and topical dermatologic and ophthalmologic therapies. The cutaneous lesions regressed, and the corneal epithelial defect closed; however, complete ptosis and ophthalmoplegia persisted, and visual acuity remained the same as the baseline in both eyes at the fourth-week follow-up. This case demonstrates that total ophthalmoplegia may be present at the initial presentation of HZO. Advanced age was the patient's major established risk factor, while asthma was his only chronic comorbidity. Asthma may represent a contributing clinical context, but a causal relationship with complicated HZO cannot be inferred from a single case.

PMID 42626581
Read full article →
PubMedAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2026-08-19

As-Needed Versus Regular Intranasal Corticosteroid Therapy in Pediatric Perennial Allergic Rhinitis: A Randomized Double-Dummy Trial.

Chatmaitri Supaluk S, Boonnijasin Ongon O, Wisitsartkul Apiradee A, Kanchanapoomi Kantima K et al.

Intranasal corticosteroids (INCS) are the most effective monotherapy for allergic rhinitis (AR), but daily adherence remains challenging. Evidence comparing regular versus as-needed INCS use in pediatric perennial allergic rhinitis (PAR) is limited. To evaluate the efficacy, safety, and anti-inflammatory effects of regular versus as-needed INCS in pediatric PAR. In this 8-week, randomized, double-blind, double-dummy trial, 70 children aged 6-18 years with PAR were assigned (1:1) to regular or as-needed intranasal fluticasone furoate. Key outcomes included total, nasal, and ocular symptom scores (TSS, TNSS, TOSS), visual analog scale (VAS), parent-assessed scores, Rhinoconjunctivitis Quality of Life-36 (RCQ-36), peak nasal inspiratory flow (PNIF), nasal cytology, INCS exposure, and adverse events. Sixty-eight patients completed the trial (as-needed, n=33; regular, n=35). Regular treatment demonstrated greater improvements in TSS, TNSS, TOSS, VAS, PVAS, and PNIF than as-needed treatment at selected early time points (all P<0.05). However, these differences were not sustained through week 8. No significant between-group differences were observed in PTSS, PTNSS, PTOSS, or RCQ-36 scores. At week 8, regular treatment yielded greater reductions in mucosal eosinophils and basophilic metachromatic cells (P<0.05). Cumulative INCS exposure was lower with as-needed treatment (P<0.05). Adverse events were comparable, although epistaxis occurred only in the as-needed group (P=0.02). Regular INCS use was associated with greater early clinical and antiinflammatory benefits than as-needed use in pediatric PAR, without increased adverse events. However, between-group clinical differences were not sustained through week 8. As-needed treatment also improved outcomes from baseline and may be an alternative for symptom control in selected patients.

PMID 42617693
Read full article →

+2127 more articles available with a free account

Sign up free to view all articles →

Ask about mometasone furoate